<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

NSABP Investigator Recounts Loyalty To Fisher, “Betrayal”

NCAB Member Seeks Broder’s Resignation, Gets No support

Pittsburgh Broadens Misconduct Inquiry

Senate Appropriators Plan Hearing On NCI Ouster Of Fisher

DCE director Adamson To Retire August 31

DCPC Advisor O Trial Of Cervical Lesion Management With HPV

NSABP Accrual To Resume Soon; Group ponders Elections, Move To Fox Chase

In Brief: Karen Antman And John Glick lead ASCO; ODAC to Meet June 7 On Tamoxifin Trial

Results of NSABP Studies Unchanged When Falsified Data is Excluded: Fisher

ASCO TO NCI: Review Auditing Procedures, Re-Establish Trust